Last reviewed · How we verify
Gut-directed budesonide and SoC
Gut-directed budesonide delivers a corticosteroid locally to the intestinal tract to reduce inflammation, combined with standard of care management.
Gut-directed budesonide delivers a corticosteroid locally to the intestinal tract to reduce inflammation, combined with standard of care management. Used for Inflammatory bowel disease (IBD) — likely Crohn's disease or ulcerative colitis.
At a glance
| Generic name | Gut-directed budesonide and SoC |
|---|---|
| Also known as | IgANEF® by MediART Life Sciences Pvt. Ltd. |
| Sponsor | Christian Medical College, Vellore, India |
| Drug class | Corticosteroid (topical/gut-directed) |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Immunology |
| Phase | FDA-approved |
Mechanism of action
Budesonide is a corticosteroid with high topical potency and low systemic bioavailability when formulated for gut delivery. The gut-directed formulation targets intestinal inflammation directly while minimizing systemic exposure. This combination approach with standard of care aims to improve efficacy in inflammatory bowel conditions.
Approved indications
- Inflammatory bowel disease (IBD) — likely Crohn's disease or ulcerative colitis
Common side effects
- Headache
- Nausea
- Abdominal pain
- Systemic corticosteroid effects (with prolonged use)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: